Fiche publication
Date publication
janvier 2022
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LAGROST Laurent
,
Pr MARTIN Laurent
,
Dr PAIS DE BARROS Jean-Paul
,
Dr DAGUINDAU Etienne
Tous les auteurs :
Chagué C, Gautier T, Dal Zuffo L, Pais de Barros JP, Wetzel A, Tarris G, Pallot G, Martin L, Valmary-Degano S, Deckert V, Lagrost L, Daguindau E, Saas P
Lien Pubmed
Résumé
Acute graft-versus-host disease (aGVHD) is a major limitation of the therapeutic potential of allogeneic hematopoietic cell transplantation. Lipopolysaccharides (LPS) derived from intestinal Gram-negative bacteria are well-known aGVHD triggers and amplifiers. Here, we explored the LPS metabolism in aGVHD mouse models using an innovative quantification method. We demonstrated that systemic LPS accumulation after transplantation was due, at least partly, to a defect in its clearance through lipoprotein-mediated transport to the liver (i.e., the so-called reverse LPS transport). After transplantation, reduced circulating HDL concentration impaired LPS neutralization and elimination through biliary flux. Accordingly, HDL-deficient (Apoa1 ) recipient mice developed exacerbated aGVHD. Repeated administration of HDL isolated from human plasma significantly decreased the mortality and the severity of aGVHD. While the potential role of HDL in scavenging circulating LPS was examined in this study, it appears that HDL plays a more direct immunomodulatory role by limiting or controlling aGVHD. Notably, HDL infusion mitigated liver aGVHD by diminishing immune infiltration (e.g., interferon-γ-secreting CD8 T cells and non-resident macrophages), systemic and local inflammation (notably cholangitis). Hence, our results revealed the interest of HDL-based therapies in the prevention of aGVHD.
Référence
Am J Transplant. 2022 Jan 17;:
